Reuters: US Judge Overturns Amgen’s US$50.3 million Loss in Cancer Drug Patent Case
August 14, 2025
A Delaware federal judge invalidated two patents owned by Lindis Biotech, undercutting a US$50.3 million jury verdict in an infringement lawsuit over Amgen’s leukemia drug Blincyto. US District Judge Gregory Williams said that the patents were unenforceable due to their inventor’s “inequitable conduct” at the US Patent and Trademark Office. The O’Melveny team advising Amgen included partners Lisa B. Pensabene, and Hassen Sayeed, and Luann L. Simmons, counsel Sorin Zaharia, associate Amy Zhao and special counsel Lindsay Autz. This story was also covered by Law360.
Read the full article here.